Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study

被引:81
|
作者
Broekaert, D [1 ]
Fischler, B [1 ]
Sifrim, D [1 ]
Janssens, J [1 ]
Tack, J [1 ]
机构
[1] Univ Leuven, Univ Hosp Gasthuisberg, Div Gastroenterol, Dept Internal Med, B-3000 Louvain, Belgium
关键词
D O I
10.1111/j.1365-2036.2006.02772.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Tricyclic antidepressants, which have multiple pharmacological influences, have a therapeutic effect in non-cardiac chest pain, but selective serotonin reuptake inhibitors have a single pharmacological effect. Aim To evaluate the acute effect of citalopram on oesophageal hypersensitivity. Methods On two separate occasions, 10 healthy subjects (seven men, mean age 25 years) with established oesophageal hypersensitivity, underwent oesophageal manometry with evaluation of mechanical and chemical sensitivity. Subjects received placebo or citalopram 20 mg i.v. in a randomized, crossover, double-blind fashion. Results Citalopram did not alter oesophageal motility. Citalopram significantly increased the threshold inducing first perception (4.6 +/- 0.3 vs. 6.7 +/- 0.4 mL, P < 0.005) and discomfort (8.6 +/- 0.4 vs. 9.9 +/- 0.6 mL, P < 0.01) during balloon distention. It also significantly prolonged the acid perfusion time to induce perception of heartburn (6.0 +/- 0.9 vs. 10.7 +/- 0.6 min, P < 0.005) and discomfort (12.2 +/- 0.8 vs. 16.7 +/- 0.7 mL, P < 0.001). Seven subjects experienced a retrosternal sensation during edrophonium provocation with placebo, and this was reduced to two of 10 after citalopram (P = 0.02). Conclusions Acute administration of citalopram significantly lowers chemical and mechanical oesophageal sensitivity in oesophageal hypersensitivity, without altering the motility.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 50 条
  • [1] Interruption of selective serotonin reuptake inhibitor treatment - Double-blind, placebo-controlled trial
    Michelson, D
    Fava, M
    Amsterdam, J
    Apter, J
    Londborg, P
    Tamura, R
    Tepner, RG
    BRITISH JOURNAL OF PSYCHIATRY, 2000, 176 : 363 - 368
  • [2] Validation of [123I]β-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram
    Maartje M L de Win
    Jan B A Habraken
    Liesbeth Reneman
    Wim van den Brink
    Gerard J den Heeten
    Jan Booij
    Neuropsychopharmacology, 2005, 30 : 996 - 1005
  • [3] Validation of [121I]β-CIT SPECT to assess serotonin transporters in vivo in humans:: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram
    de Win, MML
    Habraken, JBA
    Reneman, L
    van den Brink, W
    den Heeten, GJ
    Booij, J
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (05) : 996 - 1005
  • [4] Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-Blind, Placebo-Controlled Study
    Viazis, Nikos
    Keyoglou, Anastasia
    Kanellopoulos, Alexandros K.
    Karamanolis, George
    Vlachogiannakos, John
    Triantafyllou, Konstantinos
    Ladas, Spiros D.
    Karamanolis, Dimitrios G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11): : 1662 - 1667
  • [5] Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
    Di Girolamo, E
    Di Iorio, C
    Sabatini, P
    Leonzio, L
    Barbone, C
    Barsotti, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (05) : 1227 - 1230
  • [6] Treatment with the selective serotonin reuptake inhibitor sertraline in the early phase of acute coronary syndromes: a double-blind, placebo-controlled pilot study
    Tanzi, P
    Picano, A
    Salvini, P
    Terranova, A
    Terrana, R
    Cicini, MP
    Mercuro, G
    Pelliccia, F
    EUROPEAN HEART JOURNAL, 2004, 25 : 296 - 297
  • [7] Treatment with the selective serotonin reuptake inhibitor sertraline in the early phase of acute coronary syndromes: A double-blind, placebo-controlled, pilot study
    Pelliccia, F
    Picano, A
    Salvini, P
    Polletta, B
    Cartoni, D
    Cicini, MP
    Mercuro, G
    Tanzi, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 231A - 232A
  • [8] Citalopram in the treatment of alcoholism: A double-blind placebo-controlled study
    Tiihonen, J
    Ryynanen, OP
    Kauhanen, J
    Hakola, HPA
    Salaspuro, M
    PHARMACOPSYCHIATRY, 1996, 29 (01) : 27 - 29
  • [9] Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline
    Stahl, SM
    BIOLOGICAL PSYCHIATRY, 2000, 48 (09) : 894 - 901
  • [10] Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study
    Salokangas, RKR
    Saarijarvi, S
    Taiminen, T
    Kallioniemi, H
    Lehto, H
    Niemi, H
    Tuominen, J
    Ahola, V
    Syvalahti, E
    ACTA PSYCHIATRICA SCANDINAVICA, 1996, 94 (03) : 175 - 180